Form 4: Agios Pharmaceuticals Director Jacqualyn Fouse Reports Routine Equity Grants and RSU Conversion

Agios Pharmaceuticals Director Jacqualyn Fouse has reported the conversion of 2,120 restricted stock units into common stock and received new grants of 2,816 restricted stock units and 15,768 stock options.

Summary

• Jacqualyn Fouse, a Director at Agios Pharmaceuticals, Inc. (AGIO), reported transactions involving company equity.
• On June 20, 2025, Ms. Fouse converted 2,120 restricted stock units (RSUs) into common stock. These RSUs were originally granted on June 20, 2024, and vested in full on June 20, 2025.
• Following this conversion, Ms. Fouse directly beneficially owns 151,340 shares of common stock.
• On June 18, 2025, Ms. Fouse was granted 2,816 new restricted stock units, which are scheduled to vest in full on June 18, 2026.
• Also on June 18, 2025, she received a grant of 15,768 stock options with an exercise price of $35.5 per share. These options will vest 100% on June 18, 2026, and have an expiration date of June 18, 2035.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive, reflecting routine insider transactions that align director interests with shareholders through equity grants and the conversion of vested awards. It does not contain information that would significantly alter the company's fundamental outlook.

Positives

• New equity grants (RSUs and stock options) align the director's interests with long-term shareholder value.
• The conversion of previously granted RSUs into common stock indicates a successful vesting event and an increase in the director's direct equity ownership.

Future Outlook

The document indicates future vesting events for newly granted restricted stock units and stock options on June 18, 2026, which aligns the director's incentives with the company's future performance and long-term value creation.

Industry Context

This Form 4 filing reflects standard compensation practices for directors in the biotechnology and pharmaceutical industry, where equity grants are a common mechanism to incentivize long-term commitment and align the interests of leadership with those of shareholders.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) and stock options to a director is a common practice in the U.S. pharmaceutical and biotechnology sectors, similar to compensation structures observed at peer companies like Vertex Pharmaceuticals or Biogen.
• The vesting schedule of one year for new equity grants (June 2025 to June 2026) is a typical short-to-medium term incentive structure for director equity awards, comparable to practices at other publicly traded companies in the sector.
• The stock option exercise price of $35.5 would typically be set at the market price on the grant date, which is a standard industry practice for at-the-money option grants.

Related Party Transactions

• The equity grants (restricted stock units and stock options) and the conversion of previously granted restricted stock units are transactions between the company and a director, which are considered related-party dealings in the context of executive and director compensation.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially encouraging long-term value creation. The increase in common stock ownership by a director can be viewed positively as a sign of confidence in the company's future.

Next Steps

• Delivery of vested shares to the reporting person within three business days after June 20, 2025 (for the converted RSUs).
• Vesting of 2,816 restricted stock units on June 18, 2026.
• Vesting of 15,768 stock options on June 18, 2026.

Key Dates

Keywords

Agios Pharmaceuticals, AGIO, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership